In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates

• Published in: Virologica Sinica Vol. 37; no. 3; pp. 398 - 407
• Main Authors: Liu, Tingting, Liu, Anlei, Liu, Yong, Cen, Shan, Zhang, Quan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-06-2022; Wuhan Institute of Virology, Chinese Academy of Sciences
• Subjects: Clinical isolates; Genotype B; Genotype C; Hepatitis B virus (HBV); Infectivity; sL21S; Clinical isolates; Genotype B; sL21S; Hepatitis B virus (HBV); Infectivity; Genotype C
• ISSN: 1995-820X; 1674-0769; 1995-820X
• DOI: 10.1016/j.virs.2022.03.008

Hepatitis B virus (HBV) genotype B and C are two major genotypes that are prevalent in Asia and differ in natural history and disease progression. The impact of HBV genotypes on viral replication and protein expression has been explored by the transfection of hepatoma cells with replication-competent HBV DNA, which mimics the later stages of the viral life cycle. However, the influence of HBV genotypes on the early events of viral infection remains undetermined, mainly due to the difficulties in obtaining sufficient infectious viral particles for infection assays. Here, we report that a high-titer HBV inoculum can be generated from the transient transfection-based cell model after optimizing transfection conditions and modifying the HBV-expressing construct. By performing in vitro infection assays using transiently transfected derived viruses, we found that clinical genotype C isolates possessed higher infectivity than genotype B isolates. Moreover, we identified a naturally occurring mutation sL21S in small hepatitis B surface protein, which markedly decreased the infectivity of HBV genotype C isolates, but not that of genotype B isolates. In summary, using infectious viral particles provided by the optimized transient transfection-based cell model, we have been able to investigate a wide range of HBV variants on viral infectivity, which may contribute to our understanding of the reasons for different clinical outcomes in HBV infections and the development of therapeutic drugs targeting the early stages of HBV life cycle.
•A high-titer HBV inoculum for ​in vitro ​infection assays can be obtained from an optimized transient transfection system.•In vitro ​infection experiments revealed that HBV genotype C isolates possessed higher infectivity than genotype B isolates.•The sL21S mutation markedly decreased the infectivity of HBV genotype C isolates but not that of genotype B isolates.